Stelara 45 MG/0.5 ML syringe 0.5ML
Ended Awarded Last action
- Contract number
- SPE2DR26FQR4A
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $201,268
Award facts
- Contract value 100% obligated
- $201,268.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $201,268 delivery order to AmerisourceBergen Drug Corp for Stelara 45 mg/0.5 mL syringes on December 3, 2025, with completion targeted for December 4, 2025. The contract utilizes firm fixed pricing with no small business set-aside and identifies the vendor's Conshohocken, Pennsylvania location as the place of performance. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive pharmaceutical prime vendor agreement valued at $999,999,999 and extending through December 2026, which authorizes the company to supply an extensive range of pharmaceuticals and medical supplies to support military healthcare systems globally.
AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, holds a significant position within the Defense Logistics Agency's medical supply chain. The company's federal contract portfolio demonstrates consistent capability to competitively win awards for diverse pharmaceutical products and medical commodities supporting defense healthcare missions. The Stelara delivery order represents a discrete transaction within the broader DLA Troop Support Medical IDC framework, which is designed to provide flexible pharmaceutical sourcing across multiple therapeutic domains for military and veteran healthcare systems. The Defense Logistics Agency's upcoming Pharmaceutical Prime Vendor Global Program Generation V contracts are expected to involve multiple regional awards, underscoring the strategic importance of vendors like AmerisourceBergen in the federal pharmaceutical procurement landscape.
Quick answers
Who was awarded contract SPE2DR26FQR4A?
SPE2DR26FQR4A was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FQR4A worth?
The government has obligated $201,268 on SPE2DR26FQR4A.
Is contract SPE2DR26FQR4A an order under another contract?
Yes. SPE2DR26FQR4A is a delivery order under SPE2DR25D1022, an indefinite delivery contract.
Was contract SPE2DR26FQR4A competed?
The extent of competition for SPE2DR26FQR4A was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award